they are not intended to diagnose, treat, cure, or prevent any disease
Legal status (US): Sermorelin has a documented, two-part FDA approval history under the brand name Geref, both approvals held by Serono (later EMD Serono)
In esophageal injury models, BPC-157 demonstrated faster closure of experimentally induced ulcers compared to omeprazole (a standard PPI) at 14 days
Capsules are more convenient, but injection requires reconstitution and sterile supplies
Typical Protocol: Commonly cited protocols use 1.5-1.6 mg subcutaneously two to three times per week (mirroring the Zadaxin regimen used in hepatitis trials), often run in 4 to 16 week cycles for general wellness use, with the original clinical trials using 1.6 mg twice weekly for 6 to 12 months
The Efficacy of Oral Vitamin B12 Replacement for Nutritional Vitamin B12 Deficiency